BREAST CANCER;
CANCER CLASSIFICATION;
CANCER INVASION;
CHROMOSOME 17;
DRUG SENSITIVITY;
FLUORESCENCE IN SITU HYBRIDIZATION;
HUMAN;
IMMUNOHISTOCHEMISTRY;
LETTER;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
BREAST NEOPLASMS;
FEMALE;
HUMANS;
IMMUNOHISTOCHEMISTRY;
IN SITU HYBRIDIZATION, FLUORESCENCE;
PHOSPHOPROTEINS;
RECEPTOR, ERBB-2;
TUMOR MARKERS, BIOLOGICAL;
EID: 79955456549PISSN: 00278874EISSN: 14602105Source Type: Journal DOI: 10.1093/jnci/djr074Document Type: Letter
How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear
doi: 10.1093/jnci/djq557
Schmidt C. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear. J Natl Cancer Inst. 2011;103(2):87-89. doi: 10.1093/jnci/djq557.
Absence of chromosome 17 polysomy in breast cancer: Analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification
Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat. 2010;120(1):1-7.
Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. 2009;22(9):1169-75.
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis
Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009;219(1):16-24.
Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer-letter
author reply 6178
Moelans CB, de Weger RA, van Diest PJ. Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer-letter. Clin Cancer Res. 2010;16(24):6177; author reply 6178.
Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17
Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer. 2011;117(1):48-53.
